爱思益普已建立了400+激酶

我们的优势：

• 激酶种类多：目前已建成激酶库超过400个并不断扩大，覆盖常用酪氨酸激酶及常见突变激酶； 

• 检测准确：对于已有明确特异抑制剂的激酶选用其特异性抑制剂建立试验模型，控制IC50差异与文献报道值在5倍以内，最大不超过七倍； 

• 检测周期短：化合物检测出报告周期3-5个工作日，1-2个工作日可提交数据；

• 检测方法：TR-FRET(LANCE Ultra, LathaScreen, HTRF)，荧光法(Kinase-Glo, ADP-Glo)，Z`-LYTE，Binding assay等。

爱思益普已建立的激酶列表

部分验证数据（需要更多验证数据请联系我们）

参考文献：

[1]. SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemother Pharmacol. 2009 Sep;64(4):723-32.

[2]. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol. 2013, 191(7), 3568-3577.

[3].Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia. J Med Chem. 2012 Oct 25;55(20):8721-34.

[4]. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3(11):1427-38.

[5]. Peng SB, et al. Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition. Biochemistry, 2005, 44(7), 2293-2304.